Tafluprost and analogs thereof for reducing fat

• US 9,180,130 B2
• Filed: 12/19/2012
• Issued: 11/10/2015
• Est. Priority Date: 12/19/2011
• Status: Active Grant

• Current Assignee: Topokine Therapeutics, Inc. (Abbvie Incorporated)
• Original Assignee: Topokine Therapeutics, Inc. (Abbvie Incorporated)
• Inventors: Kalayoglu, Murat V., Singer, Michael S.
• Primary Examiner(s): Willis, Douglas M
• Application Number:
  US14/363,923
• Publication Number:
  US 20140350104A1
• Time in Patent Office: 1,056 Days
• Field of Search: 562/503
• US Class Current: 1/1
• CPC Class Codes: A61K 31/165 having aromatic rings, e.g. colchicine, atenolol, progabide
• CPC Class Codes: A61K 31/191 having two or more hydroxy groups, e.g. gluconic acid
• CPC Class Codes: A61K 31/216 of acids having aromatic rings, e.g. benactizyne, clofibrate
• CPC Class Codes: A61K 31/25 with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
• CPC Class Codes: A61K 31/5575 having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
• CPC Class Codes: A61K 8/69 containing fluorine
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61K 9/06 Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels composition of ointments, creams or gels A61K47/00
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61Q 19/005 Preparations for sensitive skin
• CPC Class Codes: A61Q 19/06 for countering cellulitis

Abstract

Provided are methods of reducing body fat in a subject, comprising locally (e.g., topically) administering one or more compounds of the Formula (I) and/or (V):

or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, polymorph, tautomer, isotopically enriched derivative, or prodrug thereof, wherein X is —OR₁, —SR₂, or —NR₃R₄, and R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₇′, Z, Y, n, y, and x, are as defined herein.

Claims

1. A method for reducing fat in a body of a subject in need thereof, the method comprising injecting into a fat deposit a compound of the Formula (II):

2. The method of claim 1, wherein the fat deposit comprises a tumor.

3. The method of claim 1, wherein the tumor is a lipoma.

4. The method of claim 1, wherein the fat deposit is excess body fat that is a side effect of a medication.

5. The method of claim 4, wherein the medication is selected from the group consisting of a corticosteroid, an anti-retroviral, an antidepressant, an oral contraceptive, and insulin.

6. The method of claim 1, wherein the composition is a sterile injectable preparation selected from the group consisting of a sterile solution, sterile suspension, and sterile emulsion.

7. The method of claim 6, wherein the sterile injectable preparation is sterilized by filtration through a bacterial-retaining filter.

8. The method of claim 1, wherein R₁ is hydrogen.

9. The method of claim 1, wherein R₁ is C₁-C₄ alkyl.

10. The method of claim 1, wherein R₁ is methyl, ethyl, isopropyl, n-propyl, n-butyl, tert-butyl, isobutyl, or sec-butyl.

11. The method of claim 1, wherein the compound is:

12. The method of claim 1, wherein the fat deposit comprises orbital fat.

13. The method of claim 1, wherein the fat deposit is localized to the abdomen, chest, breast, buttocks, hips, thighs, legs, knees, arms, chin, neck, or face.

14. The method of claim 1, wherein the subject suffers from obesity.

15. The method of claim 1, wherein the subject suffers from a condition selected from the group consisting of human immunodeficiency virus lipodystrophy, acquired lipodystrophy, and familial lipodystrophy.

16. The method of claim 1, wherein the subject suffers from gynecomastia.

17. The method of claim 1, wherein the injecting is subcutaneous.

18. The method of claim 1, wherein the injecting is intralesional.

19. The method of claim 1, wherein the composition comprises one or more pharmaceutically acceptable excipients, and the concentration of the compound in the composition is between 0.001% and 1% (w/w) or (w/v), inclusive.

20. The method of claim 1, wherein the injecting reduces the volume, size, mass, bulk, and/or density of the fat deposit.